Median Technologies is awarded the Futur40 prize, an initiative launched by Forbes France

We transform medical images into meaningful, actionable insights to help better diagnose, treat, and monitor patients. We deploy proprietary artificial intelligence, computer vision, and signal processing technologies to develop imaging tests and services, addressing life-threatening unmet medical needs.

With eyonis™ we are disrupting the management of serious diseases such as lung cancer, liver cancer, and NASH. We are deploying AI/ML Software as Medical Devices (SaMDs) to help health professionals diagnose patients earlier, treat them more effectively, and bring new hope. eyonis™ is currently under development.

Imaging Services for Clinical Trials

Median’s Imaging CRO business provides leading oncology clinical trial imaging services, empowering our life sciences partners to accelerate the development and delivery of life-saving cancer treatments with unmatched operational excellence and reliability. And we don’t stop there. We are forging the way when it comes to innovative imaging technology, leveraging the latest in AI-powered imaging intelligence to develop actionable insights for biopharma sponsors worldwide.

Learn More

Request a Demo

Press Release – For immediate release – 17:45 CEST

Median Technologies, the Imaging Phenomics Company™, announces that on July 13^th 2017, it was awarded the Futur40 Prize by Forbes France, in association with PME finance – Europe Entrepreneurs, the French Finance Association Paris Europlace and the Federation of Individual Investors and the Finance Clubs (F2iC – Fédération des Investisseurs Individuels et des Clubs d’investissement).

The criteria for obtaining the Futur40 award are as follows:

Cumulative sales growth of more than 15% over the last three years,
€ 5 million of minimum turnover, and
The company listed in Paris with a minimum stock footprint (free float, trading volume) to have certified public data.

Back to press releases